This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Abecma industry.
What is the current market size of the abecma industry, and what growth rate is it expected to achieve?
The abecma market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to approval of abecma for relapsed/refractory multiple myeloma, advancements in car t-cell therapy, rising incidence of multiple myeloma, high efficacy in treatment-resistant cases, increasing research and development investments.
The abcema market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising prevalence of multiple myeloma, expanding approved indications, advances in personalized medicine, global market expansion, improved manufacturing and cost reduction. Major trends in the forecast period include increased adoption in earlier lines of treatment, geographic market expansion, technological advancements in car t-cell therapy, combination therapy strategies, personalized and precision medicine, growing focus on relapsed/refractory multiple myeloma.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19847&type=smp
What are the major drivers contributing to the growth of the abecma market?
The rise in the prevalence of multiple myeloma is expected to propel the growth of the abecma market going forward. Multiple myeloma is a type of blood cancer that affects plasma cells, which are a type of white blood cell found in bone marrow. The rising prevalence of multiple myeloma is due to aging population, improved diagnostic techniques, and increasing awareness of the disease. Abecma, a CAR T-cell therapy, is helpful in treating multiple myeloma by utilizing genetically modified immune cells to target and destroy cancerous plasma cells, offering a novel option for patients with relapsed or refractory forms of the disease. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, there were projected to be 35,780 cases of myeloma compared to 34,470 in 2022. Therefore, The rise in the prevalence of multiple myeloma drives the abecma market.
What are the major market segments driving the growth of the abecma industry?
The abecma market covered in this report is segmented –
1) By Indication: Multiple Myeloma; B-Cell Lymphoma (BCL); Acute Lymphoblastic Leukemia (ALL)
2) By End User: Adult; Geriatric
3) By Distribution Channel: Hospitals And clinics; Retail And Speciality Pharmacies; Online Pharmacies
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/abecma-global-market-report
What are the key trends shaping the abecma market in the forecast period?
The key trend in the abecma market are focusing on developing innovative treatments such as chimeric antigen receptor T cell therapy (CAR T) to enhance patient outcomes, target specific cancer types more effectively, and expand the therapeutic options available for individuals with relapsed or refractory multiple myeloma. Chimeric antigen receptor T cell therapy (CAR T) is an advanced form of immunotherapy used primarily to treat certain types of cancers, such as leukemia and lymphoma. It involves genetically engineering a patient’s own T cells (a type of white blood cell) to better recognize and destroy cancer cells. For instance, in March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, received the approval of the European Commission (EC) for Abecma (idecabtagene vicleucel; ide-cel), a CAR T-cell therapy designed to treat adult patients with relapsed and refractory multiple myeloma. This approval specifically targets patients who have undergone at least two prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody, and who have shown disease progression following their last treatment.
Who are the key market players contributing to the growth of the abecma industry?
Major companies operating in the abecma market include Bristol-Myers Squibb
Which regions are leading the growth of the abecma market globally?
North America was the largest region in the abecma market in 2024. The regions covered in the abecma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Abecma Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19847
Need Customized Data On Abecma Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=19847&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
